The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Benmelstobart plus carboplatin/paclitaxel with or without anlotinib, followed by maintenance benmelstobart with or without anlotinib, as first-line treatment for advanced or recurrent endometrial cancer: A randomized, open-label, phase II trial.
 
Xiaojun Chen
No Relationships to Disclose
 
Keqiang Zhang
No Relationships to Disclose
 
Ke Wang
No Relationships to Disclose
 
Ruifang An
No Relationships to Disclose
 
Dong Wang
No Relationships to Disclose
 
DaPeng Li
No Relationships to Disclose
 
Ying Yang
No Relationships to Disclose
 
Chunyan Wang
No Relationships to Disclose
 
Xiumin Li
No Relationships to Disclose
 
Bingzhong Zhang
No Relationships to Disclose
 
Xunqiang Wang
Employment - Chia Tai Tianqing Pharmaceutical Group Co.Ltd.
 
Zhenling Li
Employment - Chia Tai Tianqing Pharmaceutical Group Co.Ltd.
 
Xiaojing Wan
Employment - Chia Tai Tianqing Pharmaceutical Group Co.Ltd.